HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $32 to $34.
November 02, 2023 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics' price target has been raised from $32 to $34 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Corcept Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100